Last updated on March 2017

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ovarian Cancer
  • Age: 18 Years
  • Gender: Female

Not a complete listing of criteria:

  • Stage 3 or 4 advanced, high-grade predominantly serious or endometriod ovarian, fallopian tube or primary peritoneal cancer and have completed first-line platinum-based chemotherapy (i.e. carboplatin, cisplatin) with a clinical complete or partial response
  • All those with Stage IV are eligible after primary or interval debulkingThose with Stage III must have visible disease after primary surgery. Those with Stage III or IV that cannot be operated on are eligible.
  • Must agree to have tumor HRD testing
  • Must be placed in the niraparib or placebo group within 12 weeks after the first day of the last cycle of chemotherapy
  • Must not have had more than 2 debulking surgeries
  • Must not have gotten bevacizumab (Avastin) with front-line platinum-based chemotherapy
  • Must not have been treated with a known PARP inhibitor

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.